-
Suzetrigine
API’s Name CAS No. US DMF Patent Expiry Date (US) Current Status Suzetrigine 2649467-58-1 Aug, 2026 Dec.4, 2040 estimated PV Completion – Aug, 2026 [Product]
Provide the API as well as the SDD (Spray Dried Dispersion).
[Indication]
For the management of acute pain of moderate to severe intensity in adults.
-
Semaglutide
API’s Name CAS No. US DMF Patent Expiry Date (US) Current Status Semaglutide 910463-68-2 2026 Dec.05, 2031 estimated PV Completion – 2026 [Indication]
1. As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
2. For chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity.
3. To reduce the risk of major adverse cardiovascular events (MACE) in adults with type 2 diabetes mellitus and established cardiovascular disease.
4. To reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes mellitus and chronic kidney disease.
-
Sugammadex Sodium
API’s Name CAS No. US DMF Patent Expiry Date (US) Current Status Sugammadex Sodium 343306-79-6 37085 Jan.27, 2026 Commercial Production [Indication]
1. Sugammadex is indicated for the reversal of neuromuscular blockade induced by rocuronium or vecuronium in adult patients.
2. In pediatric patients (2 to 17 years of age), sugammadex is recommended only for routine reversal of rocuronium-induced neuromuscular blockade.
-
Sacubitril Hemicalcium
API’s Name CAS No. US DMF Patent Expiry Date (US) Current Status Sacubitril Hemicalcium 1369773-39-6 Commercial Production [Indication]
1. To reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (HF) with reduced ejection fraction.
2. To reduce the risk of cardiovascular death and hospitalization in patients with heart failure with mild or moderately reduced ejection fraction or preserved ejection fraction.
3. For the treatment of adults with hypertension to lower blood pressure.
-
Sofosbuvir
API’s Name CAS No. US DMF Patent Expiry Date (US) Current Status Sofosbuvir 1190307-88-0 32048 Mar.26, 2029 Commercial Production [Indication]
1. In combination with other antiviral drugs, for the treatment of chronic hepatitis C virus (HCV) genotype 1, 2, 3, or 4 infection in adults.
2. Patients with hepatocellular carcinoma and those awaiting liver transplantation.
3. Patients with HCV/HIV-1 co-infection.
4. In combination with ribavirin, for the treatment of pediatric patients 3 years of age and older with genotype 2 or 3 chronic HCV infection without cirrhosis or with compensated cirrhosis.